Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Wave Life Sciences Ltd.NASDAQ: WVE

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $2.16M a year earlier. Trailing-twelve-month cost of revenue was $4.46M.

Context

  • Cost of revenue amounted to 20.7% of revenue in FY2025, up 20.7 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.11M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$8.85M— YoY
LTMMar 2026
$4.46M+106.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
8.85M USD
Year-over-year change
—

Cost of Revenue vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +106.0% is the 3rd highest of 7, against a peer median of +73.2%.
  • Cost of revenue amounts to 6.2% of revenue for WVE, versus a peer median of 10.3%.
WVE Competitors
Cost of Revenue for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$974.34M USD+141.9%+58.9%20.3%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$821.4M USD+102.3%+84.7%37.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$167.7M USD-26.7%+28.1%253.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M USD+44.2%+4.3%1.8%
WVEWave Life Sciences Ltd.LTM Mar 2026$4.46M USD+106.0%—6.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M USD——8.8%
STOKStoke Therapeutics, Inc.LTM Mar 2026$3.09M USD+178.5%—9.6%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$1.8M USD—-47.6%0.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
BNTCBenitec Biopharma Inc.LTM Mar 2026$119K USD-36.4%——
Peer median (excluding WVE) —+73.2%+16.2%10.3%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.